We’d love to hear your feedback on this activity. It helps us to continually improve our products.
James Comprehensive Cancer Center, Columbus, OH, USA
Dr David O’Malley is director of the Division of Gynecologic Oncology within the Department ofObstetrics and Gynecology at the James Cancer Hospital and Solove Research Institute in Columbus, OH, USA, and professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine. read more
Dr O’Malley has over 600 peer-reviewed citations and over 220 published articles, including in the New England Journal of Medicine, Lancet, Lancet Oncology, JAMA Oncology, Nature Genetics, Nature Communications and the Journal of Clinical Oncology. He serves on multiple editorial boards and has served as a committee member for the Society of Gynecologic Oncology, a member of the Developmental Therapeutics Working Group for NRG Oncology and a panel member of the National Comprehensive Cancer Network Guidelines for Ovarian Cancer (2008–2021). He currently serves as a member of the Ovarian Cancer Working Group for NRG Oncology, on the National Cancer Institute’s Gynecologic Cancer Steering Committee’s Ovarian Task Force, and as an ovarian cancer clinical trial lead at GOG Partners.Â
Dr O’Malley has been recognized as a Top Doctor since 2010. At Ohio State University, he has developed the gynaecologic oncology division into one of the premier clinical research and phase I gynaecologic oncology programmes in the country. He has led numerous clinical trials, including serving as principal investigator for multiple national and international trials.
Disclosures
Dr David O’Malley discloses: Advisory board or panel fees from AbbVie, Adaptimmune, Agenus, Arcus Biosciences, Arquer Diagnostics, AstraZeneca, Atossa Therapeutics, Boston Biomedical, Cardiff Oncology, Celcuity, Clovis Oncology, Corcept Therapeutics, DualityBio, Eisai, Elevar Therapeutics, Exelixis, Genelux, Genentech, GSK, lmmunoGen, Inc, lmvax, lnterVenn Biosciences, InxMed, Iovance Biotherapeutics, Janssen, Jazz Pharmaceuticals, Laekna, Leap Therapeutics, Luzsana Biotechology, Merck & Co, Mersana Therapeutics, MSD, Myriad Genetics, Novartis, Novocure, OncoC4, Onconova Therapeutics, Regeneron Pharmaceuticals, Replmmune, R-Pharm, Roche, Roche Diagnostics, Seagen, Sorrento Therapeutics, Sutro Biopharma, Tarveda Therapeutics, Toray, Trillium Therapeutics, Umoja Biopharma, VBL Therapeutics, Verastem Oncology, Vincerx Pharma, Xencor and Zentalis Pharmaceuticals. Grants/research support from AbbVie, Advaxis, Agenus, Alkermes, Aravive, Arcus Biosciences, Inc., AstraZeneca, BeiGene, Boston Biomedical, Bristol Myers Squibb, Clovis Oncology, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelixis, Genentech, Genmab, GSK, lmmunoGen, lncyte, Iovance Biotherapeutics, Karyopharm, Leap Therapeutics, Merck & Co, Mersana Therapeutics, MSD, Novartis, NovoCure, OncoC4, OncoQuest Pharmaceuticals, Pfizer, Precision Therapeutics, Prelude Therapeutics, Regeneron Pharmaceuticals, Roche, Rubius Therapeutics, Seagen, Sutro Biopharma, TESARO and Verastem Oncology.
La Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
Dr Domenica Lorusso is an associate professor of obstetrics and gynecology at Fondazione Policlinico Universitario A Gemelli in Rome, Italy. read more
Dr Lorusso has been involved in gynaecological oncology research for more than 25 years and has conducted or participated in approximately 200 phase I to IV clinical trials in gynaecological malignancies. At present, she is the principal investigator of more than 60 studies. Dr Lorusso is responsible for the Clinical Trials Committee of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynaecological Malignancies) Group, which includes more than 150 Italian centres involved in gynaecological oncology research. She is member of the Board of Directors of the Gynaecological Cancer Intergroup, which includes 23 international research groups involved in the promotion and implementation of high-quality clinical trials to improve outcomes for women with gynaecological cancers. Dr Lorusso is also an active member of ENGOT (European Network of Gynaecological Oncological Trial groups), where she chairs the Gynecological Cancer Academy.
Dr Lorusso has co-authored approximately 300 international oncology publications. She is an author of national and international guidelines on the treatment of ovarian, cervical and endometrial cancer. Dr Lorusso’s key goals are to promote clinical research, international trial collaborations and education.
Dr Domenica Lorusso discloses: Advisory board or panel fees from AstraZeneca, Clovis Oncology, Corcept, Genmab, GSK, ImmunoGen, MSD, Oncoinvent, Pharmamar, Seagen and Sutro. Consultancy fees from AstraZeneca, Clovis Oncology, Corcept, Genmab, GSK, ImmunoGen, MSD, Novartis, Oncoinvent, Pharmamar, Seagen and Sutro. Grants/research support from AstraZeneca, Clovis Oncology, Genmab, GSK, ImmunoGen, Incyte, MSD, Novartis, Pharmamar, Roche and Seagen. Speakers’ bureau fees from AstraZeneca, Clovis Oncology, Genmab, GSK, ImmunoGen, MDS, Pharmamar and Seagen.
Ohio State University, Columbus, OH, USA
Ms. Courtney Arn is a women’s health nurse practitioner in the Division of Gynecologic Oncology at The Ohio State University (OSU), Columbus, OH, USA. read more
After graduating from the OSU College of Nursing, Ms. Arn undertook the Women’s Health Care Nurse Practitioner Core Board Certification. Ms. Arn specializes in the treatment of women with gynaecological cancers, covering ovarian, uterine, peritoneal, endometrial, cervical, vaginal and vulval cancer.
Ms. Courtney Arn discloses: Speakers’ Bureau fees from AstraZeneca, Eisai, Genmab, GSK, Merck and Seagen.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Or use a
.Explore the latest in medical education and stay current in your field. Create a free account to track your learning.